Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05286801
Title	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	atypical teratoid rhabdoid tumor collecting duct carcinoma epithelioid sarcoma rhabdoid cancer Advanced Solid Tumor chordoma
Therapies	Atezolizumab + Tiragolumab
Age Groups:	adult \| senior \| child
Covered Countries	USA \| CAN \| AUS